Aniracetam
3 sources
How the databases line up — = agree, ≈ partial, ≠ differ. In lists, shared items appear in every source and unique ones in only one (matched case-insensitively).
Show:
| PsychonautWiki | TripSit | Pharmacology | ||
|---|---|---|---|---|
| Classification | ||||
| Class / category | — | ≈ | ||
| Also known as | Aniracetam | — | — | |
| Safety | ||||
| Addiction potential | non-addictive with a low potential for abuse | — | — | |
| Dangerous interactions | — | — | ||
| Dose · Oral | ||||
| Threshold | 350 mg | — | — | |
| Light | 500–1200 mg | — | — | |
| Common | 1200–1800 mg | — | — | |
| Strong | 1800–2400 mg | — | — | |
| Heavy | 2400 mg+ | — | — | |
| Duration | ||||
| Onset | 45–90 minutes | — | — | |
| Total | 3–5 hours | 2–4 hours | — | ≠ |
| After-effects | — | 1–4 hours | — | |
| Pharmacology | ||||
| Receptor activity | — | — | GluA1GluA2GluA3GluA4 | |
| Half-life | — | — | 1-2.5 hours | |
Duration at a glance
Total duration on one shared scale.
PsychonautWiki
TripSit
TripSit summary
An anxiolytic nootropic which modulates the AMPA receptor. Significantly more potent than racetam. May have positive effects on memory and cognition. Little recreational value. Sold in Europe as a prescription drug, but not approved by the FDA in the US.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.